Global stock

XETRAEUR

Bayer AG

BAYN.DE

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

48/ 100

Overall score·BAYN.DE

Current price

43.98EUR

23/10/2026

P/E, P/B

Valuation

Strong

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E 9,1 a EV/EBITDA 7,63 ukazují na relativně nízké ocenění, avšak PEG 4,65 a záporný zisk na akcii oslabují argument pro podhodnocení. Nejslabšími dimenzemi jsou stabilita kvůli vysokému zadlužení a ziskovost se zápornou čistou marží; tržby rostou jen mírně a krátkodobé momentum je slabé.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 55%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at Bayer AG (BAYN.DE) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

48/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

41/100

Slightly negative signal based on current news, price action and the economy.

74/100

A lower score means the stock is expensive relative to the company's earnings and assets.

20% below fair value

An estimate of what the stock should be worth based on the company's future cash.

+1%

How fast the company's revenue grows year on year.

35/100

How much the company earns from each unit of revenue and from invested capital.

28/100

Debt level, share-price volatility and how resilient the company is in bad times.

56/100

AI estimate of management quality, execution and capital allocation.

72/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

William N. Anderson je předsedou představenstva a CEO; mezi členy vedení jsou také CFO Judith Hartmann a Stefan Oelrich, prezident farmaceutické divize. Bayer se zaměřuje na obnovu růstu farmaceutického portfolia, zlepšení provozní výkonnosti a zvládnutí právních závazků i zadlužení.

Articles about Bayer AG, in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

3 November 2026

in 7 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Bayer AG (BAYN.DE)?

Bayer AG (BAYN.DE) is a global stock traded on XETRA. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Bayer AG price today?

As of 23 October 2026, Bayer AG trades at about 43.98 EUR per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Bayer AG?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Bayer AG pay a dividend?

Bayer AG either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Bayer AG a good investment in 2026?

Our AI signal currently rates Bayer AG as slightly negative (score 41/100). Financial health comes out at 48/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 20 % below its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Bayer AG

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly negative

Earnings in 7 days

On 3 November 2026 the company publishes its quarterly results. This period tends to bring large price moves — the signal below does not reflect the results yet.

News summary

No newer news

Signal 02/10, 12:01

Zprávy naznačují spíše negativní výhled pro Bayer v krátkém období; slabý technický signál s downtrendem a RSI blízko překoupení/short-term pokles.

Krátkodobý sentiment naznačuje obavy z výkonu, technika ukazuje pokračující pokles (trend −) a RSI na 30 naznačuje přeprodání, nicméně 7–30denní změna ceny naznačuje spíše volatilní pohyb bez výrazného obratu. Dlouhodobě může působit makro tlak na farmaceutický sektor a regulační rizika.

Risks: Riziko makro prostředí a specifických regulačních posunů v EU/Nemecku; oslabení cen komponent, případné pozitivní terapeutické výsledky mohou změnit trend; překonání rezistence 50denních klouzavých průměrů by změnilo outlook.

More about the signal

Signal history· 1

25/0920:0177 · Strongly positive
Bayer získává pozitivní sentiment z nedávných cenových pohybů a technické ukazatele potvrzují uptrend.

The full 90-day signal history is part of Premium.

Ask the AI

§ Model fair value (DCF)

Fairly valued20% below fair value

54.71

range 44.0 – 69.6

Current price

43.98 EUR

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

54.71 EUR

range 44.0 EUR – 69.6 EUR

: 4.0%
: 9.5%
: 3.50 EUR

Růst FCF 4 % p.a. je konzervativní předpoklad vzhledem k nízkému růstu tržeb a zápornému zisku, přestože ověřený výchozí FCF je kladný. Diskontní sazba 9,5 % zohledňuje zvýšené finanční a podnikatelské riziko; terminální růst 2,5 % odpovídá dlouhodobě udržitelnému tempu. Při těchto předpokladech model naznačuje hodnotu citlivou na vývoj budoucího FCF.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 16 of 18

Valuation score

3/ 6

5/6 tests available

1. Below DCF fair value

19.6% below the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

51% above the 1-year low (34.10 EUR to 53.36 EUR), based on stored daily prices.

4. P/E vs. similar companies

The sector sample has only 72 companies; scoring needs at least 8.

5. P/E relative to growth

PEG 4.7; a lower value means cheaper growth.

6. Analyst price target

32.4% vs. the current price, 18 analysts.

Price vs DCF

Current price

43.98 EUR

Low 43.96 EURHigh 69.63 EUR

Current priceDCF midpoint: 54.71 EUR

Price vs analyst target

Current price

43.98 EUR

Low 46.00 EURHigh 70.00 EUR

Current priceAverage: 58.22 EUR

DCF gap

within range

The price is within the model range of 43.96 EUR to 69.63 EUR.

Analyst target

+32.4%

Average target 58.22 EUR vs. price 43.98 EUR.

Analyst consensus

Target range

46.00 EUR - 70.00 EUR

Coverage

18 analysts

Analyst consensus

1.9 / 5

Changes 180 d

+0 / -0

EPS next year

6.8%

Revenue next year

2.6%

Valuation multiples

9.1

1.5

1.0

7.6

4.7

52-week range51% above the low

34.10 EUR53.36 EUR

1.0%

-3.8%

-5.7%

Price vs 50D-7.4%

Price vs 200D1.3%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

good

Vedení pokračuje v investicích do výzkumu a rozvoje portfolia, avšak výsledky zatěžují právní spory a vysoké zadlužení, což omezuje hodnocení exekuce a alokace kapitálu.

strong

Bayer těží z globálního rozsahu, zavedených značek a výzkumného zázemí ve farmacii i zemědělství. Trvanlivost této výhody oslabují právní závazky a rizika spojená s úspěchem vývoje nových produktů.

Information

Type: Global stock
Symbol: BAYN.DE
Exchange: XETRA
Currency: EUR
Sector: Healthcare
: 43.4B USD
: 129.4 %
: 0.84

§ Risk profile

Zásadními riziky jsou náklady a nejistota soudních sporů kolem herbicidu Roundup, vysoké zadlužení a tlak na peněžní toky. Českému investorovi navíc výnos v korunách ovlivňuje kurz EUR/CZK.

Ask the AI about Bayer AG All signals